Medivir AB News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.02.19	Medivir's Chief Financial Officer Erik Björk Leaves the Company (PR Newswire)
21.12.18	First Patient With Colorectal Cancer Dosed in the Phase ll Study of Birinapant in Combination With Keytruda® (PR Newswire)
14.12.18	The Transformation Into a Company Focused on Clinical Development of Pharmaceuticals has now been Completed and Medivir Gives a Project Update (PR Newswire)
26.10.18	Medivir AB - Interim Report January - September 2018 (PR Newswire)
19.10.18	New Data From the MIV-711 Phase II Program Will be Presented at the ACR Annual Meeting on October 21 (PR Newswire)
17.10.18	Medivir Scales Back Research Costs to Focus on Clinical Development (PR Newswire)
04.10.18	Positive Interim Data on Birinapant in Combination With Keytruda® (PR Newswire)
10.09.18	Medivir Appoints Dr. Linda Basse as Chief Medical Officer (PR Newswire)
02.08.18	Investigator-initiated Phase II Clinical Study of Remetinostat Started in Patients With Basal Cell Carcinoma (PR Newswire)
27.07.18	MIV-711 Osteoarthritis Phase IIa Extension Study Outcomes Show Continuing Positive Effect on Joint Structure (PR Newswire)
25.07.18	Medivir AB - Interim Report January - June 2018 (PR Newswire)
28.06.18	Medivir Announces Positive Top-line Results From the MIV-711 Osteoarthritis Phase IIa Extension Study (PR Newswire)
18.06.18	Continued Discussions With FDA on Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study (PR Newswire)
31.05.18	Phase I/II Study Design of Birinapant in Combination With Keytruda® to be Presented on June 4 at the ASCO Annual Meeting (PR Newswire)
18.05.18	Additional Remetinostat Phase II Data Will be Presented at the International Investigative Dermatology Meeting on May 18 and 19 (PR Newswire)
03.05.18	Resolutions at the Annual General Meeting in Medivir on 3 May 2018 (PR Newswire)
30.04.18	Number of Shares and Votes in Medivir (PR Newswire)
27.04.18	Medivir AB - Interim Report January - March 2018 (PR Newswire)
26.04.18	Medivir AB: Data From the MIV-711 Initial Phase IIa Study Will be Presented at the OARSI World Congress on April 27 (PR Newswire)
13.04.18	New Preclinical Data on MIV-818 Will be Presented at the AACR Annual Meeting in April (PR Newswire)
04.04.18	Notice of Annual General Meeting of Medivir AB (publ) (PR Newswire)
04.04.18	Medivir's Annual Report for 2017 is Published (PR Newswire)
28.03.18	Conversion of all Class A Shares in Medivir to Class B Shares - Prospectus Published (PR Newswire)
15.03.18	Medivir - The Nomination Committee´s Proposal for New Board of Directors to the Annual General Meeting 2018 (PR Newswire)
01.03.18	Medivir: New Preclinical Data on MIV-818 Accepted for Presentation at EASL's HCC Summit in March (PR Newswire)
28.02.18	Number of Shares and Votes in Medivir (PR Newswire)
22.02.18	Global Automotive Filter Market Report 2018 (PR Newswire)
14.02.18	Medivir AB - Year End Report January - December 2017 (PR Newswire)
26.01.18	Resolutions at the Extraordinary General Meeting in Medivir on 26 January 2018 (PR Newswire)
16.01.18	Europe Data Centre Trends Tracker 2018: Frankfurt is Set to Become the Largest Third Party Data Centre Cluster in Europe (PR Newswire)
08.01.18	Successful Completion of Pre-clinical Safety Studies With MIV-818, Enabling Start of Phase I Clinical Studies in 2018 (PR Newswire)
02.01.18	Medivir's Series A Shares to be Converted Into Series B Shares (PR Newswire)
02.01.18	The Medivir Board is Seeking Issue Authorizations to Increase the Company's Funding Flexibility and Calls for an Extraordinary General Meeting (PR Newswire)
10.12.17	Medivir Announces Janssen Decision to Terminate its Simeprevir License Effective June 2018 (PR Newswire)
10.11.17	Medivir Appoints Christina Herder as Executive Vice President Strategic Business Development (PR Newswire)
09.11.17	Medivir: MIV-711 Phase IIa Osteoarthritis Study Data Presented as a Late Breaking Poster at the Annual Meeting of the American College for Rheumatology (PR Newswire)
08.11.17	Medivir Announces New Cancer Project, Leukotide, Derived from its in-house Nucleotide Platform (PR Newswire)
03.11.17	Medivir Appoints Erik Björk as Chief Financial Officer (PR Newswire)
26.10.17	Medivir AB - Interim Report, January - September 2017 (PR Newswire)
23.10.17	Data on the Clinical Activity of Simeprevir in Combination With AL-335 and Odalasvir (JNJ-4178) Presented at the 2017 Liver Meeting™ (PR Newswire)
20.10.17	MIV-711 Phase IIa Osteoarthritis Study Data Selected as Late Breaking Abstract at the Annual Meeting of the American College for Rheumatology (PR Newswire)
13.10.17	Remetinostat Phase II Data Demonstrate Efficacy on Skin Lesions, Reduction of Itching and High Tolerability in Patients With Early-stage MF-type CTCL (PR Newswire)
05.10.17	AMR Centre Deal With Medivir Targets Superbug Time-bomb (PR Newswire)
11.09.17	Medivir Announces Janssen to Discontinue Development of JNJ-4178 for Hepatitis C (PR Newswire)
01.09.17	Global UV Curable Resins & Formulated Products Market to Reach $7.6 Billion by 2025 - Growing Demand in 3D & Digital Printing Applications (PR Newswire)
18.08.17	Medivir Initiates Clinical Study of Birinapant in Combination With KEYTRUDA® (Pembrolizumab) in Patients With Treatment-refractory Solid Tumours (PR Newswire)
18.08.17	Medivir Licenses Exclusive Rights to MIV-802 for Greater China to Ascletis (PR Newswire)
16.08.17	FDA Accepts Medivir´s IND Application for MIV-711, Enabling Clinical Development in the US (PR Newswire)
02.08.17	Nordic Nanovector Appoints Dr. Reza Safaei as Head of Medical Affairs (PR Newswire)
25.07.17	Medivir AB - Interim Report, January - June 2017 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swisscom	527.00	2.33 %	K V
Holcim	95.34	1.21 %	K V
UBS Group	30.42	0.86 %	K V
Roche Hldg G	289.00	0.45 %	K V
Swiss Re	141.65	0.35 %	K V
Givaudan	3’850.00	-1.48 %	K V
Lonza Grp	603.80	-1.50 %	K V
Alcon	82.30	-1.53 %	K V
Geberit	508.00	-1.74 %	K V
Part Grp Hldg	1’386.00	-2.26 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Medivir AB

Aktien Top/Flop

Meistgelesene Nachrichten